Peethambaram P, Weiss M, Loprinzi C L, Novotny P, O'Fallon J R, Erlichman C, O'Connell M J, Laurie J A
Mayo Clinic, Rochester, Minn. 55905, USA.
Oncology. 1997 Jul-Aug;54(4):287-92. doi: 10.1159/000227705.
Currently patients with colon cancer who are potentially cured by surgery are followed periodically with physical examinations, blood tests and imaging studies to detect tumor recurrence early, on the presumption that intervention can effect outcome. There is little information to indicate whether frequent visits to the doctor's office or frequent testing improves survival or quality of life.
Ninety-eight patients with resected stage B2, B3 or C (modified Astler-Coller) colon cancer who developed recurrent disease while enrolled in prospective adjuvant trials at Mayo Clinic sponsored by the North Central Cancer Treatment Group were studied to evaluate the utility of follow-up tests to detect the first recurrence of colon cancer and the outcome following various interventions for these recurrences. These patients had a history, physical examination, complete blood count, chemistry panel and chest x-ray approximately every 3-4 months in the 1st year and then every 6-12 months thereafter for a total of 5 years. Bowel evaluation was done at 6 months, 12 months and annually thereafter. In addition, a minority of patients had carcinoembryonic antigen (CEA) testing, and radioisotope liver scans at various intervals.
Symptoms signaled the diagnosis of recurrent disease in 55 patients, physical examination in 4 patients, and abnormalities in chest x-ray in 18 patients. An elevated CEA was the initial abnormal test in 5 patients, abnormal liver scans in 5 patients, elevated liver function tests in 6 patients and laparotomy for other reasons in 2 patients. Hemoglobin, barium enema, and fecal blood testing were useful in 1 patient each. Thirty-one percent of recurrences were diagnosed between scheduled visits. In our series, histories, physical examinations, and chest x-rays led to the detection of 79% of the recurrences while liver function tests, liver scans and CEAs led to the detection of 16% of recurrences. Sixteen patients underwent resection for cure for their first recurrence; the diagnosis of recurrence was signaled by symptoms in 6 patients, chest x-ray in 6 patients and abnormal liver function tests, CEA, hemoglobin, and laparotomy for colostomy closure in 1 patient each.
The majority of tumor recurrences were detected by symptoms, physical examinations and chest x-rays. Testing for asymptomatic tumor recurrences during the 1st follow-up year is likely to be much less fruitful for detecting resectable recurrences than testing patients in the 2nd through 4th follow-up years. Patients who had a disease recurrence in the 1st postoperative year were less likely to be candidates for curative intent surgery. Lower tumor grade at initial diagnosis correlated both with likelihood of undergoing secondary surgical resection and the chance of doing well following this. These data may be helpful for defining more appropriate follow-up test for detection of tumor recurrence in patients with resected colon cancer.
目前,对于有可能通过手术治愈的结肠癌患者,会定期进行体格检查、血液检测和影像学检查,以期早期发现肿瘤复发,前提是干预措施能够影响预后。但几乎没有信息表明频繁就医或频繁检测能否提高生存率或生活质量。
对98例在由北中部癌症治疗组赞助的梅奥诊所前瞻性辅助试验中发生复发性疾病的B2、B3或C期(改良阿斯特勒-科勒分期)结肠癌患者进行研究,以评估随访检测在发现结肠癌首次复发中的作用以及针对这些复发采取各种干预措施后的预后。这些患者在第1年大约每3 - 4个月进行一次病史采集、体格检查、全血细胞计数、血液生化检查和胸部X光检查,此后每6 - 12个月进行一次,共持续5年。肠道评估在6个月、12个月时进行,此后每年进行一次。此外,少数患者还在不同间隔时间进行癌胚抗原(CEA)检测和放射性核素肝脏扫描。
55例患者的症状提示了复发性疾病的诊断,4例通过体格检查,18例通过胸部X光异常。5例患者最初的异常检测是CEA升高,5例是肝脏扫描异常,6例是肝功能检查升高,2例因其他原因进行了剖腹手术。血红蛋白、钡灌肠和粪便潜血检测各对1例患者有用。31%的复发是在预定就诊间隔期间被诊断出来的。在我们的系列研究中,病史、体格检查和胸部X光检查发现了79%的复发,而肝功能检查、肝脏扫描和CEA检测发现了16%的复发。16例患者因首次复发接受了根治性切除手术;复发的诊断在6例患者中由症状提示,6例由胸部X光提示,1例由肝功能检查异常、CEA、血红蛋白以及因结肠造口关闭进行的剖腹手术提示。
大多数肿瘤复发是通过症状、体格检查和胸部X光检查发现的。在第1年随访期间检测无症状肿瘤复发对于发现可切除的复发情况可能比在第2至4年随访期间检测患者的效果要差得多。术后第1年出现疾病复发的患者不太可能成为根治性手术的候选者。初始诊断时肿瘤分级较低与接受二次手术切除的可能性以及术后良好预后的机会均相关。这些数据可能有助于确定更合适的随访检测方法,以发现接受结肠癌切除患者的肿瘤复发情况。